

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6945269

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
HARPOON THERAPEUTICS, INC.	06/18/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	TCR2 THERAPEUTICS INC.
<b>Street Address:</b>	100 BINNEY STREET, SUITE 710
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02142
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15888897
<b>Application Number:</b>	16989606
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6504939300
<b>Email:</b>	patentdocket@wsgr.com, bmaclean@wsgr.com
<b>Correspondent Name:</b>	WILSON SONSINI GOODRICH ROSATI
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304
<b>ATTORNEY DOCKET NUMBER:</b>	48538-702.301, 303
<b>NAME OF SUBMITTER:</b>	MENGMENG ZHANG
<b>SIGNATURE:</b>	/Mengmeng Zhang/
<b>DATE SIGNED:</b>	09/30/2021
<b>Total Attachments: 2</b>	
source=48538702301harpoontotcrassignment#page1.tif	
source=48538702301harpoontotcrassignment#page2.tif	

WHEREAS, **HARPOON THERAPEUTICS, INC.**, a corporation incorporated under the laws of the State of Delaware, having a place of business at 131 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080 (US); (hereinafter "Assignor"), owns its entire right, title and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

**COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS**

- for which application serial number 15/888,897 was filed on February 5, 2018 and issued as Patent No. 10,208,285 on February 19, 2019 in the United States Patent and Trademark Office;
- for which application serial number 16/222,846 was filed on December 17, 2018 in the United States Patent and Trademark Office;
- for which application serial number 16/989,606 was filed on August 10, 2020 in the United States Patent and Trademark Office;

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, **TCR2 Therapeutics Inc.**, a corporation incorporated under the laws of the State of Delaware, having a place of business at 100 Binney Street, Suite 710, Cambridge, Massachusetts 02142 (US), (hereinafter "Assignee"), is desirous of acquiring its entire right, title and interest in and to said Inventions, and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee its entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby requests that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

**CORPORATE TO CORPORATE ASSIGNMENT**

Docket Number 48538-702.301, 302, 303

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

**ASSIGNOR**


**HARPOON THERAPEUTICS, INC.**

Date: 6/18/21

By:   
Name: Holger Wesche  
Title: CSO

RECEIVED AND AGREED TO BY ASSIGNEE: **TCR2 Therapeutics Inc.**

Date: 6/24/2021

By:   
Name: Cristin Berkey  
Title: Intellectual Property Counsel